U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07614061) titled 'Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer' on May 22.
Brief Summary: BTC-Ag-T (ACH-AgT001) is an autologous experimental T-cell therapy designed for advanced biliary tract cancer. This is an open-label, single-arm Phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of BTC-Ag-T in patients with advanced, unresectable, or metastatic biliary tract cancer who have failed standard-of-care therapy.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Biliary Tract Neoplasms
Cholangiocarcinoma, Intrahepatic
Cholangiocarcinom...